DexCom, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? DexCom, Inc. trades at $90.23 (market cap $33.79B), while ABRDN Physical Gold Shares ETF trades at $41.9. The key difference: DexCom, Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | SGOL | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $89.53 | $51.41 |
52-Week Low | $54.84 | $31.61 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
SGOL trades at $42.21, up 0.98% with a bullish technical signal from moving averages, though oscillators show caution with RSI at overbought levels. The gold ETF benefits from recent CPI data showing cooling inflation and strong central bank demand, with spot gold prices testing key resistance levels. Financial ratios remain unavailable for this commodity-focused ETF structure.
The outlook remains positive given gold's momentum and macroeconomic support, though overbought conditions suggest potential near-term consolidation. Key risks include Fed policy shifts and dollar strength, while institutional buying provides underlying support for the gold thesis.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →